J&J: 2022 EPS down 13% at $6.73

(CercleFinance.com) - The pharma group has announced a 4.
4% drop in Q4 2022 sales to 23.7 billion dollars, mainly due to unfavourable FX factors and a drop in sales of its COVID-19 vaccine compared to 2021.

Q4 2022 EPS reached $1.33, down 24.9%, while adjusted EPS was $2.35, up 10.3%.

FY sales growth reached 1.3% at 94.9 billion dollars, mainly due to sound commercial management, although this was partly offset by unfavourable FX factors.

EPS came in at $6.73 in 2022, down 13.8%, while adjusted EPS was $10.15, up 3.6%.


Copyright (c) 2023 CercleFinance.com. All rights reserved.